Health Care·Biotechnology·$6.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-4.07 | N/A | -304.98% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-4.07 | N/A | -304.98% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategy despite current setbacks.
The earnings report shows a significant miss on EPS, which indicates ongoing challenges for Arcellx Inc. Despite this, the stock saw a slight increase of 0.11%, suggesting that investors may be looking beyond the current results. The lack of guidance could lead to uncertainty in the near term as the company navigates its strategy moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Feb 23, 2026